INNODIA and INNODIA HARVEST have leveraged an EU-wide, best-in-class collaborative clinical trials network for T1D. This network accelerates the execution of multiple clinical trials at once, and ensures effective development and accessibility of future drugs for people living with T1D. By strengthening and extending the INNODIA HARVEST trial network by satellite centres in many European countries, people living with T1D and their families have access to experts, centres and innovative trials in their home country. The INNODIA HARVEST Patient Advisory Committee (PAC) represents a link to the project’s stakeholders and was instrumental in building trust for people living with T1D.
Besides the impact on people living with T1D, the INNODIA HARVEST clinical trial network supports pharmaceutical companies is developing new immunomodulatory therapies. To successfully develop those new drugs and therapy options, pharmaceutical companies rely on clinical expertise and effective infrastructures in Europe to successfully execute development plans, which we provided during INNODIA HARVEST. In addition, INNODIA HARVEST created a master protocol describing how new studies should be developed, allowing interim analysis and different interventions to be combined in a single trial. The aim is to gain more knowledge as quickly as possible about the effect of drugs and their impact on the progression of T1D in children, adolescents and adults. The established interim analyses helps to decide whether individual interventions or combinations of interventions are promising and whether it makes sense to pursue the approach further. This master protocol can be consulted for future trial designs by pharmaceutical companies or other stakeholders. To continue this work, a non-profit organization INNODIA iVZW has been created on July 28, 2022 (
https://www.innodia.org/(si apre in una nuova finestra)). INNODIA iVZW offers scientific expert advice, access to accredited clinical trial sites, clinical trial support, education and training activities, and access to data and samples. Additionally, it provides insights from the professional experiences of people and families living with T1D. By doing so, the organization engages a diverse array of stakeholders, including medicine developers, clinical trial sites, research and innovation labs, individuals living with T1D, and entities interested in T1D research and solutions. With these goals in mind, The INNODIA iVZW is established as a platform to access smart clinical trial expertise and data on an ability-to-pay basis. Thereby, INNODIA.org is the interface between those who want to develop new therapies and those who have the expertise and tools to do so. The network is constantly expanding and currently comprises 98 members, including 85 clinical trial sites, with the overall goal to foster T1D research and development in Europe. Furthermore, the tight collaboration of INNODIA HARVEST scientists across Europe has been a nucleus to extend the focus towards prediction and prevention in T1D within a new IHI consortium (EDENT1FI).
In summary, INNODIA HARVEST had a strong impact on newly diagnosed T1D patients and their families by offering access to different clinical interventions and disease modifying therapies in various European countries, providing vision and hope.
